News

€1bn in EU funding for health and raw materials
Enlarge image

PoliticsEUPolandItalySpainUK

€1bn in EU funding for health and raw materials

16.12.2014 - Two consortia combined of 144 European companies, research institutes and universities have been selected for funding by the EIT in the areas of health and raw materials. Both clusters are set to acquire €1.1bn over the next seven years.

The European Institute of Innovation and Technology (EIT) has selected the consortium InnoLife as the Knowledge and Innovation Community (KIC) for EIT Health, which will receive a total of €700m. The funding from the EU will be invested over a period of seven years and will be supplemented by financing from the private sector interested in start-ups and applied research.

The European branch of InnoLife will be headquartered in Munich at the Technical University and will coordinate the consortium partners, which consists of 50 core players and 90 associated partners from 16 countries. “Innolife’s goal is to promote entrepreneurship and develop innovations in healthy living and active ageing, providing Europe with new opportunities and resources by delivering products, services and concepts that will improve quality of life and contribute to the sustainability of healthcare across Europe,” said Dr. Ursula Redeker from Roche Diagnostics GmbH in Munich, the coordinating partner. Other big players include Abbott Laboratories from Spain, Roche, Siemens and Philips together with research institutes such as the French National Institute of Health and Medical Research (INSERM), the University of Oxford and Imperial College London.

The second cluster is RawMatTERS, bringing together a consortium of 116 partner organisations from 22 EU member states. RawMatTERS specialises in resource efficiency and will receive €410m in funding. The partners include the KGHM Polish Copper S.A. from Poland, the RISE Research Institute of Sweden and the University of Milano-Bicocca from Italy.

As with InnoLife, the consortium will be coordinated in Germany at the Helmholz-Zentrum Dresden-Rossendorf. “The EIT will enable our partnership to make a real societal change and to turn the challenge of raw materials dependence into a strategic strength for Europe,” said Jens Gutzmer from the Helmholz research centre. We want to focus on sustainable growth and job creation by boosting start-ups, SMEs and education. By 2022, we are aiming to create, among others, 64 start-ups and 5 new primary/secondary sources of critical raw materials.”

The EIT will provide both winning clusters with a start-up grant of up to €4m to ensure a smooth and rapid start to their work in the first year.

© european-biotechnology-news.com/jc

http://www.european-biotechnology-news.com/news/news/2014-04/eur1bn-in-eu-funding-for-health-and-raw-materials.html

M&ALuxembourg

11.12.2014 Luxembourg bio-analytical testing company Eurofins Scientific has signed an agreement to acquire Boston Heart Diagnostics Corp. for an initial €112m.

StudySwitzerlandEU

10.12.2014 When it comes to the biggest investors in Research and Development (R&D) Swiss pharma top dogs Novartis and Roche have defended their positioning among the top ten companies worldwide – according to a recently published EU study.

FinancingUKSpain

09.12.2014 British drug delivery specialist Midatech Pharma plc floated on the London stock market. It is the third biotech IPO on the AIM market this year.

CooperationAustria

05.12.2014 Austrian contract research company VTU has entered into a development and commercialisation agreement with US company RCT. The partners want to combine both companies' Pichia pastoris protein production technologies under VTU's roof.

FinancingDenmark

03.12.2014 Danish biotech pharma Ascendis has successfully completed a €48m Series D financing round. The funding is expected to support its late-stage clinical trials to push its lead drug into Phase III trials.

RegulationUKFranceGermanySpain

01.12.2014 In spite of innovative new medicines on the market, the UK and Germany lag behind other countries and continue to use older medicines - especially in the treatment of cancer. French and Spanish patients, on the other hand, benefit much earlier from medical innovation.

RegulationItalyGermanyNetherlandsEU

28.11.2014 The first gene therapy for a rare genetic condition — UniQure's Glybera — is on its way to the European market. But there is a hefty price tag: Chiesi, responsible for the marketing of the orphan drug, is asking for a record price of €1.1m per patient.

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/news/pos/2.html?cHash=807fa298e991d514ff878d4f7a870d11&sort=desc

Events

All Events

Current issue

All issues

Product of the week

Products